ethyl 3-(4-benzyloxyphenyl)lactate | 141109-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 3-(4-benzyloxyphenyl)lactate
• 英文别名: 3-(4-Benzyloxyphenyl)-2-hydroxypropionic acid ethyl ester；ethyl 2-hydroxy-3-(4-phenylmethoxyphenyl)propanoate
• CAS: 141109-83-3
• 化学式: C₁₈H₂₀O₄
• 分子量: 300.354
• InChiKey: PDLNMIOGVVWRJI-UHFFFAOYSA-N

物化性质

• 沸点：
  450.1±35.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-benzyloxyphenyl)lactate 在 palladium on activated charcoal 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 18.0h， 生成 3-(4-hydroxyphenyl)-2-phenylpropionic acid ethyl ester
  参考文献：
  名称：

  Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

  摘要：

  We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with anti hyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having alpha-substituted-beta-phenylpropionic acids. In this series, we obtained potent PPARalpha/gamma dual agonist (S)-9d, with which activation of PPARalpha and PPARgamma was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARalpha/gamma dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARalpha/gamma agonistic activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.01.048
• 作为产物：
  描述：

  Ethyl-2,3-epoxy-3-(4-benzyloxyphenyl)propionate 在 三氟化硼乙醚 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 为溶剂， 以67%的产率得到ethyl 3-(4-benzyloxyphenyl)lactate
  参考文献：
  名称：

  4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

  摘要：

  Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic beta-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPAR alpha, PPAR gamma and PPAR beta/(delta). We were interested in designing novel PPAR gamma selective agonists and/or dual PPAR alpha/gamma agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.067
• 作为试剂：
  描述：

  Ethyl-2,3-epoxy-3-(4-benzyloxyphenyl)propionate 、 氢气 在 钯 ethyl 3-(4-benzyloxyphenyl)lactate 作用下， 以 1,4-二氧六环 为溶剂， 反应 15.0h， 以to afford the title compound of the formula (10) (100-105 g, 80-83%)的产率得到ethyl 3-(4-benzyloxyphenyl)lactate
  参考文献：
  名称：

  Process for the preparation of new antidiabetic agents

  摘要：

  本发明涉及一种改进的制备新型抗糖尿病化合物的过程，其化学式为（1），其中R1代表氢或低碳基团，X代表氢或卤素原子。

  公开号：

  US06531596B1

文献信息

• Amidocarboxylic acid derivatives
  申请人：Sankyo Company, Limited

  公开号：US06528525B1

  公开（公告）日：2003-03-04

  Amidocarboxylic acid derivatives of the formula: wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; X represents a substituted or unsubstituted aryl group, etc.,; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.; and pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as the active ingredient of pharmaceutical compositions. They may be used to treat specified diseases, including diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.

  公式为：其中R1代表氢原子，等等；R2代表烷基团；R3代表氢原子，等等；R4代表氢原子，等等；X代表取代或未取代的芳基团，等等；Y代表氧原子，等等；Z代表烷基团，等等；W代表烷基团，等等；以及其药理学上可接受的盐和药理学上可接受的酯作为药物组合物的活性成分是有用的。它们可用于治疗特定疾病，包括糖尿病、高脂血症、动脉硬化、高血压等。
• 3-phenylpropionic acid derivatives
  申请人：Majka Zbigniew

  公开号：US20060160870A1

  公开（公告）日：2006-07-20

  The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 to R 8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  该发明涉及新化合物，化学式(I)中的3-苯丙酸衍生物，其中W代表COOH基团或其生物同位素，或—COO—C1-C4-烷基基团；Y代表NH、N—C1-C10-烷基、O或S；X代表O、S、NH、N—C1-C10-烷基、N-芳基、NSO2—C1-C10-烷基、N—SO2-芳基或N—SO2-杂芳基；R1至R8各自独立地代表氢原子或描述中定义的取代基；A如描述中所定义；n代表从0到4的整数（包括0和4）；以及其药学上可接受的盐。这些化合物是PPAR-γ受体的配体，可用作药物。
• 3-Phenylpropionic acid derivatives
  申请人：Majka Zbigniew

  公开号：US20060160868A1

  公开（公告）日：2006-07-20

  The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; Z represents NH, N—C 1 -C 10 -alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 , to R 6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  该发明涉及新化合物，为公式I的3-苯基丙酸衍生物，其中W代表COOH基团或其生物异构体，或-COO-C1-C4-烷基基团；Y代表NH，N-C1-C10-烷基，O或S；Z代表NH，N-C1-C10-烷基，N-芳基，N-杂环芳基，S或O；X代表O，S，NH，N-C1-C10-烷基，N-芳基，NSO2-C1-C10-烷基，N-SO2-芳基或N-SO2-杂环芳基；R1至R6各自独立地代表氢原子或描述中定义的取代基；A如描述中所定义；n表示0至4的整数，包括0和4；以及其药学上可接受的盐。这些化合物是PPAR-gamma受体的配体，可用作药物。
• [EN] NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES ET LEUR UTILISATION EN MEDECINE, PROCEDE DE PREPARATION DE CES DERNIERS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1999019313A1

  公开（公告）日：1999-04-22

  (EN) Novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.(FR) La présente invention concerne de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués répondant à la formule (I) et des compositions les contenant. Ces composés sont utilisés comme agents hypolipémiants et antihyperglycémiants.

  (EN) Novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses. (中文翻译) 新型的公式（I）中的$g(b)-芳基-$g(a)-氧代取代烷基羧酸和含有它们的组合物。这些化合物具有降血脂和抗高血糖的作用。
• [EN] NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES ET LEUR UTILISATION EN MEDECINE, PROCEDE DE PREPARATION DE CEUX-CI ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2000050414A1

  公开（公告）日：2000-08-31

  The present invention relates to novel hypolipidemic, antihyperglycemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β-aryl-α-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及新型降脂、抗高血糖、抗肥胖和降胆固醇化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。更具体地说，本发明涉及一般式(I)的新型β-芳基-α-氧基取代烷基羧酸及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。